| Active substance | belantamab mafodin |
| Holder | GSK |
| Status | Closed |
| Indication | multiple myeloma in adult patients, who have received at least four prior therapies and whose disease is refractory to at least one proteasome inhibitor, one immunomodulatory agent, and an anti-CD38 monoclonal antibody, and who have demonstrated disease progression on the last therapy |
| Public documents | Approbation |
| Information for the patient | |
| Informed consent | |
| Last update | 09/08/2022 |